Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Haleon PLC ( (GB:HLN) ) just unveiled an update.
Haleon PLC announced the purchase of 4,150,000 ordinary shares as part of the second tranche of its share buyback program. The company plans to hold these shares as treasury shares, impacting its registered share capital and the number of shares with voting rights. This move is part of Haleon’s strategic financial management, potentially affecting shareholder interests and market positioning.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £380.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Spark’s Take on GB:HLN Stock
According to Spark, TipRanks’ AI Analyst, GB:HLN is a Outperform.
Haleon PLC’s overall stock score reflects a strong financial foundation with robust profitability and cash flow management. However, technical indicators and valuation suggest a more cautious outlook. The earnings call highlighted regional strengths but also significant challenges in North America, impacting the overall sentiment. The absence of notable corporate events leaves the focus on financial and operational performance.
To see Spark’s full report on GB:HLN stock, click here.
More about Haleon PLC
Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health through its diverse product portfolio. The company operates in six major categories: Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. Haleon is known for its trusted brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren.
Average Trading Volume: 20,192,836
Technical Sentiment Signal: Sell
Current Market Cap: £30.23B
Find detailed analytics on HLN stock on TipRanks’ Stock Analysis page.